


b.well Connected Health: The \$120M Infrastructure Play Quietly Powering Every Major Health AI Launch of 2026

MAR 30, 2026 • PAID



Share

Table of Contents

Introduction: The Un-AI Company

What b.well Actually Built

The Partnership Sequence That Changes the Story

The Technical Architecture Nobody Talks About

The Data Refinery as a Real Moat

Health Skills and the Product Roadmap Signal

The Competitive Risks Worth Taking Seriously

The Investment Thesis

Abstract

b.well Connected Health is a Baltimore-based health data infrastructure company founded in 2015 by Kristen Valdes and Bryan Jones. Total disclosed funding is approximately \$116M across 10+ rounds, with the most recent being a \$40M Series in February 2024 followed by \$20M in Trinity Capital growth debt in July 2025. The company has not publicly disclosed a valuation but is trading on Nasdaq Private Market.

Key facts: 2.4 million provider connections, 350+ health plan and lab connection FHIR-native canonical data model, 13-step proprietary Data Refinery, four SDK surfaces (Web TypeScript, Android Kotlin, iOS Swift in progress, AI via MCP), white-label AI assistant called bailey, and a compliance product line tied to NCQA-certified digital quality measures.

Partnership sequence Oct 2025 through Mar 2026: Google (Oct 2025), SDK launch (Dec 2025), OpenAI/ChatGPT Health (Jan 2026), bailey white-label (Feb 2026), athenahealth point-of-care workflow (Feb 2026), Samsung/Kill the Clipboard (Mar 2026), Perplexity Health (Mar 2026).

Confirmed tech stack via sub-processor disclosure (effective Jan 5, 2026): AWS (infrastructure), Databricks (data processing), MongoDB (database), Redis (caching), Fivetran (ETL), Sigma Computing (analytics/BI), Groundcover (observability), Sentry (errors), Wiz (cloud security), Dscope (identity), CLEAR (identity verification), CloudBees (feature flags), Mixpanel (app analytics), Iterable/Twilio (communications) Tonic.ai (synthetic data/de-identification).

Additional confirmed from GitHub and 2021 tech blog: Apache Kafka (event streaming), Elasticsearch (search), ClickHouse (OLAP analytics), GraphQL (query layer), CQL (clinical quality logic), Kubernetes/Helm (deployment), Python (data engineering), Node.js (FHIR API server).

Open investment questions: current valuation unknown, no disclosed revenue or customer metrics, iOS SDK still listed as coming soon, Torch acquisition by OpenAI creates internalization risk, Microsoft chose HealthEx over b.well for Copilot Health.

Introduction: The Un-AI Company

There is a company sitting at the center of the most important AI health launches of the past six months that has not raised a mega-round, has not been on the cover of anything, and most people in health tech have never heard of. That company is bConnected Health, and the reason it does not get written about is exactly the rea

is worth understanding. It is not building AI. It is building the thing AI needs to work in healthcare at all.

To get the full picture, back up to January 7, 2026. OpenAI announced ChatGPT Health, its dedicated health AI product that allows users to connect their actual medical records to their conversations with the model. The announcement was huge. The coverage was everywhere. The thing most of that coverage missed, buried in the press release, was that the health data connectivity infrastructure powering the thing was b.well. Not OpenAI's in-house data team. Not a bespoke API integration built by some well-funded startup. A Baltimore company with under \$120M in disclosed capital that had spent the better part of a decade building the plumbing nobody else wanted to build.

That is not a lucky break. By the time the OpenAI deal landed, b.well had already signed Google (October 2025), launched the first SDK designed specifically for health AI assistants (December 2025), introduced a white-label AI assistant called baile (February 2026), partnered with athenahealth on bidirectional point-of-care data sharing (February 2026), expanded a two-year Samsung partnership into a full Korea Clipboard implementation at HIMSS (March 2026), and signed Perplexity for its health product (March 2026). That is five major platform partnerships in five months each one with one of the most prominent technology companies on earth, all funneling through the same data layer.

The framing that matters here is infrastructure versus application. Applications are acquired, disrupted, or commoditized. Infrastructure, if it becomes the standard, is buried into the foundation and stays. The question for investors and founders watching this space is whether b.well has actually become infrastructure, or whether it just looks that way from the press release cadence.

What b.well Actually Built

The company's official description calls it a FHIR-native digital health platform and a connected health data network. That is technically accurate and almost completely useless for understanding what it does. Here is the more useful version.

b.well spent roughly a decade quietly onboarding as a trusted third party to ever major payer and provider in the country, leveraging the information blocking rule and patient access API mandates created by the 21st Century Cures Act and CMS interoperability regulations. By the time those regulations had teeth, b.well already had two million provider connections and three hundred payer connections. The network is the foundation. Everything else, all the AI products, all the SDK surf all the enterprise software, runs on top of that foundation.

The network connects through multiple interoperability rails simultaneously. Patient Access APIs mandated under ONC (g)(10), which are the richest data pathway because they require USCDIv3 content including unstructured clinical notes. TEFCA QIP for the national exchange layer, though TEFCA only operates at USCDIv1, means is less data-rich than the direct API connections. Regional HIEs and HINs. CMS Button for Medicare. The VA. Proprietary pharmacy and lab networks. Payer claim APIs. The March 2026 technical blog post by Yelena Balin on the resource hub runs the competitive argument plainly: companies that claim 90% coverage by counting EHR vendor logos are using a meaningless metric because a single physician can document care across four different EHR systems at four different organizations if you are only counting vendor relationships you are missing three of those four completeness requires NPI-level onboarding at individual clinic locations, not just system-level agreements.

On top of the network sits the Data Refinery. b.well describes it as a 13-step proprietary process that has been in development for a decade. What that means in practice is a pipeline that ingests data in every format healthcare has ever produced including X12 claims, HL7 v2 messages, C-CDA documents, CSV files, and JSON APIs, converts everything into standardized FHIR R4 resources, and then runs a sequence of cleansing, validation, deduplication, normalization, enrichment, and compression steps before the data touches any downstream application or AI system. The CTO Imran Qureshi published a detailed technical walkthrough of this in January 2026 on the resource hub, including a worked example of a single prescription generating six separate records across EMR, HIE, pharmacy, insurance, patient access and refill systems, each with overlapping but incomplete information, and how the

refinery reconciles those into one clean current-state record. That is not a market story. That is the actual problem, and it is actually hard.

The refinery's commercial importance for AI is the 10x LLM token reduction claim. Raw FHIR bundles are verbose, redundant, and expensive to process. A patient's complete medication history as raw FHIR JSON might cost several hundred tokens per medication entry. The refinery compresses, reconciles, and structures that into a dense, AI-optimized representation. The compressed-fhir repository on GitHub is a technical implementation of that. Multiply the cost difference across every Chat Health user who connects their records and runs health conversations, and the economic case for b.well sitting between the patient's data and the language model becomes obvious.

The Partnership Sequence That Changed the Story

The most important thing to understand about the Q4 2025 through Q1 2026 partnership run is the pattern it reveals, not the individual deals.

Google signed in October 2025 with a focus on personalizing health data for Fitbit and AI use cases. That deal was initially vague in scope and the Google product had not yet shipped a dedicated health AI product. The b.well SDK for Health AI launched in December 2025, described as the first SDK built specifically to power healthcare AI assistants, with pre-built configurations for LLMs, chatbots, copilots and agent-based systems. OpenAI signed in January 2026 and immediately used the SDK to connect ChatGPT Health to real patient records. Samsung expanded its year partnership in March 2026 to implement Kill the Clipboard at HIMSS, turning Galaxy phones into portable health record portals powered by b.well's network and CLEAR's identity infrastructure. Perplexity announced in March 2026 the same month it shipped Perplexity Health, with b.well handling the EHR connectivity layer while Perplexity handled Apple Health and wearable data through Terra API.

Three things are notable about this sequence. First, every company that needed patient EHR data for an AI health product came to the same solution. That is no

coincidence. FHIR APIs have been public for years. These companies could have their own connectivity. They chose not to because the hard part is not speaking] it is the decade of relationship-building with individual provider organizations, patient identity verification layer, the consent management infrastructure, and t data normalization work. None of those things can be bought off the shelf or replicated quickly.

Second, b.well specifically names Anthropic in its developer documentation along with OpenAI and Google as MCP client configuration targets. There is a dedicated configuration guide for Claude on the developer portal at developer.bwell.com. This is not a signed partnership announcement, but it is developer documentation that does not get built unless there is either a live integration or an active conversation about one.

Third, Microsoft went a different direction and used HealthEx for Copilot Health which launched in March 2026. That is the most important competitive data point in the entire picture because it tells you the market is not winner-take-all and b.well is not yet the universal standard. Understanding why Microsoft chose differently reveals both the limits of b.well's current position and the strategic risk on the table.

The Technical Architecture Nobody Talks About

The sub-processor disclosure from January 5, 2026 is the most unexpectedly revealing document b.well has published. Sub-processor disclosures are required for health companies under HIPAA and GDPR to inform clients of every vendor that may have access to their data. Most companies publish these as dry legal compliance documents. b.well's disclosure essentially maps the operational substrate of the platform.

Infrastructure is AWS. That is standard. The interesting part is that AWS Health Accelerator is also listed as a past investor, which means b.well has a strategic relationship with AWS that goes beyond vendor-customer. Databricks is confirmed for data processing, meaning the heavy-lift transformation layer, including the

refinery pipelines, runs in Databricks on top of AWS. MongoDB is the database, which means the canonical FHIR documents and consumer-facing longitudinal records live in a document store rather than a relational database. Redis handles caching. Fivetran moves data for internal analytics. Sigma Computing is the internal BI and data visualization layer.

Beyond those core components, Tonic.ai is listed for de-identification and synthetic data generation. That is a specialized tool used by mature engineering organizations to create realistic but PHI-free test datasets that mirror production data structures. It tells you how well has a sophisticated testing and QA environment that never exposes real patient data to development workflows. CloudBees handles feature flags, meaning new product features ship behind flags that can be toggled per customer segment or user cohort. That is how you safely roll out AI features in a regulated healthcare environment without pushing untested functionality to all users simultaneously.

The 2021 technology team blog by Qureshi adds the components that predate the current sub-processor list and remain part of the stack. Elasticsearch is named explicitly alongside Spark, AWS, Python, and Node.js as core platform technologies. The FHIR server GitHub repository confirms Kafka event streaming. The FHIR repo also has a clickhouse-init folder, confirming ClickHouse as an analytics layer. The combination makes sense: MongoDB holds the canonical records and serves real-time application queries, Elasticsearch indexes those records for full-text search and clinical note retrieval, ClickHouse handles population health analytics and HED measure calculations, and Kafka is the event bus that keeps all three in sync when data arrives.

The GraphQL layer on top of the FHIR server, also named in the 2021 blog and confirmed by the repo, is a meaningful architectural detail for the AI use case. Standard FHIR REST calls return entire resource bundles even when you only need a few fields. GraphQL lets the MCP tools request precisely the data needed for a given query, “give me active medications, most recent HbA1c, and current allergies for patient,” in a single request rather than multiple REST calls. Combined with the compressed-fhir library that reduces token footprint, this is the actual mechanism

behind the 10x LLM cost reduction claim. It is precision extraction plus compute, not magic.

The platform name in the 2021 blog is Helix. The external branding has evolved internally the product still appears to be called Helix, visible in the Helm deployment repository at github.com/icanbwell/helm.helix-service. The FHIR server at fhir.perf.icanbwell.com runs on version 3.2.60, which provides a development environment URL for direct API testing without going through the enterprise proxy.

The Data Refinery as a Real Moat

The refinery's public description includes the first few of its 13 steps: data conversion (everything to FHIR), data cleansing (fixing typos, standardizing formats, correcting invalid codes), and the beginning of a deduplication and quality assurance step. The rest of the 13 steps are not publicly disclosed. That is deliberate intellectual property protection. But the framing is enough to understand what it does at a category level.

The problem the refinery solves is that FHIR compliance is largely fictional in the real world. b.well's March 2026 technical blog by Balin points out that a substantial portion of data labeled as FHIR-compliant fails basic validation standards. Systems claim FHIR support while producing malformed or incomplete resources. Units are inconsistent across systems. Patient names change and different systems capture different versions. Medications appear as multiple records representing transaction history rather than current state. Clinical notes and care plans sit in unstructured documents with references that cannot be queried meaningfully without text extraction and embedding. A standard FHIR aggregator that just pipes through what it receives passes all these problems downstream to the application layer. The refinery is what intercepts and fixes them.

The competitive moat is not the refinery concept. It is the accumulated institutional knowledge of where healthcare data breaks. Every edge case that has been encountered and handled over ten years of onboarding providers, payers, and pharmacies is encoded in the refinery's 13 steps. A new entrant can build a FHIR aggregation layer in months. Building the clinical vocabulary mapping tables, the

deduplication logic that handles the same medication described as Lisinopril, lisinopril 10mg, and Zestril 10mg oral tablet in different source systems, the ten logic that resolves conflicting encounter dates from different systems, and the p matching rules that handle name changes, address variations, and demographic c takes years and requires touching real production data across thousands of sour organizations.

The Tonic.ai sub-processor listing adds a layer to this story. b.well is not just ru the refinery on production data. It has a parallel synthetic data infrastructure th generates test datasets mimicking real production data patterns without exposin actual patient records. That capability is what allows the engineering team to bu and test new refinery steps against realistic edge cases without ever touching PH development. That is an engineering practice that compounds quality over time.

The oidc-auth-lib repository on GitHub is another signal along the same lines. b built and maintains its own OIDC authentication library on top of the Descope : CLEAR identity infrastructure. OIDC is the protocol layer; Descope handles ide orchestration; CLEAR provides biometric IAL2 verification. Three layers of ider infrastructure because the problem requires it. Consumer-mediated health data access requires that the entity authorizing data sharing is verifiably the patient, bad actor with a stolen password. IAL2 identity proofing means that the patient' identity has been verified against government documents, not just confirmed by email or phone number. Building that at scale and making it frictionless enough patients will actually use it is a hard problem that took years to solve.

Health Skills and the Product Roadmap Signal

The March 6, 2026 blog post from Qureshi titled Health AI Needs Skills, Not Ju Intelligence is the most forward-looking technical document on the resource hu deserves serious attention because it signals the next major product direction.

The argument starts with a worked example. A patient with rheumatoid arthritis: Humira who has a documented egg allergy asks a simple question: do I need a fl

vaccine? A standard LLM answers correctly for a hypothetical healthy patient but dangerously incorrectly for this specific patient, because the right answer involves knowing that Humira as a TNF inhibitor creates enough immunosuppression to contraindicate live vaccines, that most flu vaccine formulations are egg-based, that egg-free alternatives like Flublok exist, that timing vaccination mid-cycle between biologic doses optimizes immune response, and that the specific health system's rheumatology protocols, formulary preferences, and referral pathways matter for actually executing the recommendation. The LLM has academic knowledge from medical training data. It does not have practical clinical knowledge from years of treating immunocompromised patients. It does not have organizational knowledge about how a specific health system operates.

Health Skills are b.well's answer to this problem. They are described as structured workflows written in plain English that teach bailey how to navigate specific clinical scenarios with practical and organizational context baked in. The flu vaccine skill for an immunocompromised patient is different from the flu vaccine skill for a healthy adult. Each skill encodes clinical judgment and health system-specific protocols that generic AI training data does not contain.

This is a significant product direction signal for three reasons. First, the Health Skills library becomes a proprietary asset that accumulates over time. Each skill deployment represents institutional clinical knowledge that is not available to any AI platform without a b.well relationship. The more health systems deploy bailey with their organizational protocols embedded in Health Skills, the wider the accuracy gap between bailey and any competing AI assistant without that contextual grounding. Second, it positions bailey's Chat Completions API as something meaningfully different from a thin FHIR retrieval wrapper over a foundation model. The OpenAI-compatible interface lowers the barrier to evaluation, but the actual value proposition is the combination of complete longitudinal records plus clinical workflow intelligence plus organizational context. Third, Health Skills represent a new revenue line and a new switching cost. Once a health system's clinical protocols are encoded in bailey's Health Skills library, replacing bailey requires re-encoding all of that organizational knowledge in a new system.

The Competitive Risks Worth Taking Seriously

Four risks deserve serious treatment without the marketing filter.

OpenAI bought Torch in January 2026 for approximately \$100M in an acqui-hire. Torch was a four-person health records startup building technology specifically to unify fragmented medical data for AI use. The team joined OpenAI's ChatGPT 4o service. That is a direct technical overlap with what b.well provides. OpenAI is currently a b.well customer. The Torch acquisition signals that OpenAI intends to build at least some of that capability internally over time. The optimistic read is even with Torch's team, OpenAI will find the decade of network relationships and refinery edge cases impossible to replicate quickly. The pessimistic read is that if OpenAI has its own capability, the b.well relationship becomes optional rather than essential.

Microsoft chose HealthEx over b.well for Copilot Health. Copilot Health launched in March 2026 claiming connections to more than 50,000 US hospitals and provider organizations. That is a direct competing network claim. Whether HealthEx's coverage is comparable in data completeness to b.well's, or whether it achieves breadth at the cost of the depth the Balin coverage-versus-completeness argument describes, is not determinable from public evidence. But Microsoft's choice not to partner with b.well for its consumer AI health product is the single most important competitive data point available and the one that gets the least attention in coverage of b.well's recent partnership run.

Apple controls its own health data rails through HealthKit on iOS. The b.well iOS SDK is listed as "coming soon" on the developer portal. Apple has no incentive to route patient data through b.well when it controls the native health data infrastructure for approximately 57% of US smartphone users. The Samsung partnership is Android-first by necessity, not preference. Perplexity Health connects to Apple Health through Apple's own integration and to EHR data through b.well. That is a segmented architecture that reflects the reality of Apple's walled garden.

a unified b.well-first strategy. Any investment thesis on b.well needs to account for the fact that the iOS path is structurally constrained.

The sub-processor list is missing Elasticsearch as a disclosed vendor even though confirmed in the 2021 tech blog as a core platform technology. That discrepancy either means Elasticsearch has been phased out in favor of ClickHouse or Databricks vector capabilities, or it means Elasticsearch is internal infrastructure that does not technically sub-process client data in the HIPAA sense. The distinction matters because Elasticsearch's role in the full-text search and clinical note retrieval layers is the part most directly relevant to the AI SDK's claimed search capabilities. If b.well is migrating away from Elasticsearch toward a vector database or ClickHouse's native vector search, that is a meaningful architectural transition in progress.

The Investment Thesis

The core thesis is straightforward but requires resisting the temptation to map b.well onto familiar digital health company archetypes.

b.well is not a patient engagement company. It is not an EHR. It is not a payer technology company. The closest analogy is a data network utility, something more like Plaid for healthcare than like any of the companies it gets compared to in the health tech press. Plaid built the bank connectivity network that every fintech product depends on. Plaid's value was not the applications built on top of it. Plaid's value was the network and the API abstraction layer. Visa eventually acquired it for \$5.3B before the deal fell apart on antitrust grounds.

b.well's network, the 2.4M provider connections and 350+ payer connections with NPI-level depth and multi-pathway redundancy, took a decade to build and cannot be replicated by a well-funded startup writing checks. That is the primary asset. The Data Refinery is the secondary asset, because it is the thing that makes the network output actually usable for AI rather than merely compliant. The Health Skills list and the consent/identity infrastructure are the emerging tertiary assets.

The strategic acquirer logic is strong on multiple dimensions. Google has an act partnership and is still building its consumer AI health product. Microsoft has a competitor product using HealthEx but may want b.well's network depth for future builds. Amazon Web Services launched Amazon Connect Health in March 2026 competing agentic AI layer for clinical workflows and is already an investor and infrastructure provider. Samsung is a partner and investor. Any of the AI platforms currently using b.well's SDK could determine that internalizing the infrastructure cost is worth paying a strategic acquisition premium rather than continuing to pay per-API-call licensing fees. The question of timing on any of those paths is genuinely unknowable.

The IPO path is murkier. b.well does not have the consumer brand recognition of Hinge Health or Omada Health, whose IPOs in 2025 reopened the digital health public market. It is infrastructure, and infrastructure companies tend to trade on revenue multiples that require disclosed revenue to anchor. There are no disclosed customer metrics, no case studies with named outcomes data, and no public revenue figures. That absence is either aggressive IP and contract protection (the enterprise contracts may prohibit disclosure), or it means the consumer-scale metrics are not large enough to publish without generating skepticism. A serious investor diligence process would probe that gap hard.

The honest summary is this. b.well has built something technically real and strategically positioned in a way that would have been hard to predict even three years ago. The company bet on consumer-mediated, patient-controlled health data interoperability as the long-term infrastructure layer for the entire digital health ecosystem at a time when most of the industry was building closed, proprietary data silos. That bet has paid off in the AI era because the AI companies cannot build what they need without the infrastructure b.well spent a decade creating. The partner run of the past six months is validation, not origin. The risks are real, the competitive dynamics are still evolving, and the Microsoft-HealthEx data point deserves more scrutiny than it has gotten. But the core thesis, that owning the data normalization and consent layer between fragmented healthcare records and AI systems is a durable strategic position, holds.



3 Likes • 1 Restack

[← Previous](#)

Discussion about this post

Comments

Restacks



Write a comment...

